Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
Drug results: 4
| carbidopa | An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself. |
|
| entacapone | Entacapone is a selective and reversible inhibitor of COMT. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease. |
|
| foscarbidopa | Foscarbidopa and foslevodopa combination (ABBV-951) was aproved by PMDA for the treatment of motor fluctuations in patients with advanced Parkinson’s disease. Foscarbidopa and foslevodopa are prodrugs of carbidopa and levodopa, respectively. They have higher solubility than their parent compounds, which allows them to be administered as a continuous subcutaneous infusion. |
|
| foslevodopa | Foslevodopa and foscarbidopa combination (ABBV-951) was aproved by PMDA for the treatment of motor fluctuations in patients with advanced Parkinson’s disease. Foscarbidopa and foslevodopa are prodrugs of carbidopa and levodopa, respectively. They have higher solubility than their parent compounds, which allows them to be administered as a continuous subcutaneous infusion. |
|








Citing DrugCentral © 2026.
License